CARL (Carlsmed, Inc. Common Stock) Stock Analysis - News
Carlsmed, Inc. Common Stock (CARL) is a publicly traded Healthcare sector company. As of May 21, 2026, CARL trades at $11.77 with a market cap of $297.13M and a P/E ratio of -5.59. CARL moved +4.07% today. Year to date, CARL is -2.65%; over the trailing twelve months it is flat. Its 52-week range spans $8.50 to $17.19. Analyst consensus is strong buy with an average price target of $18.40. Rallies surfaces CARL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in CARL news today?
Carlsmed Posts 58% Revenue Growth, Raises 2026 Guidance to $72–77M: Carlsmed generated $16.1 million in Q1 revenue, a 58% increase year-over-year, and raised full-year 2026 revenue guidance to $72–77 million. A retrospective study showed a 74% reduction in revision surgeries with aprevo personalized lumbar implants, and the corra cervical system debuted in February.
Carlsmed Posts 58% Revenue Growth, Raises 2026 Guidance to $72–77M: Carlsmed generated $16.1 million in Q1 revenue, a 58% increase year-over-year, and raised full-year 2026 revenue guidance to $72–77 million. A retrospective study showed a 74% reduction in revision surgeries with aprevo personalized lumbar implants, and the corra cervical system debuted in February.
Does Rallies summarize CARL news?
Yes. Rallies summarizes CARL news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is CARL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CARL. It does not provide personalized investment advice.
